Samantha Meltzer-Brody, MD, director, perinatal psychiatry program, University of North Carolina at Chapel Hill. “FDA approves first treatment for post-partum depression,” FDA News Release.
Brexanolone (Zulresso) is FDA-approved to treat postpartum depression, which puts mother and healthy child development at risk. Learn more.